Intra-Cellular Therapies (ITCI) Stock

Intra-Cellular (ITCI) saw an increase in its share price during the last trading session, with higher-than-normal trading volume. However, the recent changes in earnings estimates for the stock do not indicate that this upward trend will continue in the future.

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is looking into Intra-Cellular Therapies (Nasdaq: ITCI) for potential breaches of fiduciary duty and legal violations related to its deal with Johnson & Johnson. To find out how to participate in our investigation and get more details, click here or reach us at [email protected] or call toll-free: 866-264-3995. There is no cost or obligation involved. In this deal, Intra-Cellular Therapies shareholders will receive just $132.00 per share in cash.

Intra-Cellular Therapies (ITCI) saw its shares jump 35% in premarket trading on Monday after Johnson & Johnson (JNJ) announced plans to buy the biopharmaceutical firm for about $14.6 billion.

The acquisition includes CAPLYTA® (lumateperone), which is the first and only treatment approved by the U.S. FDA for bipolar I and II depression, both as a standalone therapy and in combination with other treatments. It is also approved for treating schizophrenia in adults.

According to Bloomberg News, Johnson & Johnson is considering making an offer to buy Intra-Cellular Therapies Inc, a company that specializes in biopharmaceuticals. This information comes from sources who are knowledgeable about the situation.

CAPLYTA experienced impressive revenue growth, reaching $125.8 million in net product revenues for Q3 2024, marking a 39% increase compared to the previous year. There is a chance for even higher revenue if CAPLYTA is approved as an additional treatment for major depressive disorder, which is a significant area of need. Additionally, Lenrispodun, a PDE inhibitor, is currently in a phase 2 trial for Parkinson's Disease, with results expected by late 2025 or early 2026, presenting another major opportunity.

Intra-Cellular has filed a supplemental New Drug Application (sNDA) with the FDA to expand the use of Caplyta for treating Major Depressive Disorder (MDD) in adults, specifically as an additional treatment alongside antidepressants.

On December 3, 2024, Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company that develops treatments for central nervous system disorders, announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA). This application is for CAPLYTA (lumateperone) to be used as an additional treatment for Major Depressive Disorder (MDD) in adults alongside antidepressants.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) will hold its Q3 2024 Earnings Conference Call on October 30, 2024, at 8:30 AM ET. The call will feature company representatives including Juan Sanchez, Sharon Mates, Mark Neumann, Sanjeev Narula, and Suresh Durgam. Various analysts from firms like Jefferies, JPMorgan, and Goldman Sachs will also participate in the call.